Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Galapagos Rises Most in Three Years in Brussels on Abbott Deal

Feb. 29 (Bloomberg) -- Galapagos NV rose the most in more than three years in Brussels trading after agreeing to license an experimental drug to Abbott Laboratories.

Galapagos climbed 26 percent to 13.69 euros at 9:20 a.m. The stock’s intraday gain was the biggest since Feb. 13, 2009.

Link to Company News:{ABT US <Equity> CN <GO>} Link to Company News:{GLPG BB <Equity> CN <GO>}

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.